Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C

Translational Research

Volumn 148, Issue 2, 2006, Pages 79-86

  Hosogaya, Shigemi ^a,b,c   Ozaki, Yukio ^a,b,c   Enomoto, Nobuyuki ^a,b,c   Akahane, Yoshihiro ^a,b,c  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c Kofu Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENZYME; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SEX RATIO; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 33746483224     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.03.004     Document Type: Article

References (23)

1. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Hepatology 12 (1990) 671-675
2. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide I., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma. Ann Intern Med 131 (1999) 174-181
3. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Koida I., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis. a prospective observation of 2215 patients. J Hepatol 28 (1998) 930-938
4. Imai Y., Kawata S., Tamura S., Yabuuchi I., Noda S., Inada M., et al., Osaka Hepatocellular Carcinoma Prevention Study Group. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 15 (1998) 94-99
5. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96 (1995) 224-230
6. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334 (1996) 77-81
7. Arase Y., Chayama K., Ikeda K., Tsubota A., Suzuki Y., Saitoh S., et al. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hapatitis C. Hepatol Res 21 (2001) 55-66
8. Thevenot T., Regimbeau C., Ratziu V., Leroy V., Opolon P., and Povnard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients. 1999 update. J Viral Hepat 8 (2001) 48-62
9. Kakumu S., Yoshida K., Wakita T., Ishikawa T., Takayanagi M., and Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105 (1993) 507-512
10. Cummings K.J., Lee S.M., West E.S., Cid-Ruzafa J., Fein S.G., Aoki Y., et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. a meta-analysis of randomized trials. JAMA 285 (2001) 193-199
11. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 (2003) 2095-2100
12. Enomoto N., Takada A., NaKao T., and Date T. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 170 (1990) 1021-1025
13. Doumas B.T., Bayse D.D., Carter R.J., Peter T.J., and Schaffer R. A candidate reference method for determination of total protein in serum. I. Development and validation. Clin Chem 27 (1981) 1642-1650
14. Otsuji S., Mizuno K., Ito S., Kawahara S., and Kai M. A new enzymatic approach for estimating total and direct bilirubin. Clin Biochem 21 (1988) 33-38
15. Scientific Division of Japan Society of Clinical Chemistry. Proposed standard for certified enzyme reference material. Jpn J Clin Chem 25 (1996) 135-148
16. Truett J., Cornfield J., and Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chron Dis 20 (1967) 511-524
17. Hosmer D., and Lemeshow S. Applied logistic regression. 1st ed (1989), Wiley, New York 135-75
18. Suzuki H., and Tango T. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with high-titer chronic hepatitis C virus infection. Hepatol Res 22 (2002) 1-22
19. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343 (2000) 1673-1680
20. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
21. Bressler B.L., Guindi M., Tomlinson G., and Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003) 639-644
22. Giannini E., Ceppa P., and Testa R. Steatosis in chronic hepatitis C. can weight reduction improve therapeutic efficacy?. J Hepatology 35 (2001) 432-433
23. Villela-Nogueira C.A., Perez R.M., de Segadas Soares J.A., and Coelho H.S. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 39 (2005) 728-730